Savara Inc (SVRA)

Savara Inc (SVRA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1B; returns 1 day -7.0%, 1 week -5.2%, 1 year +2.4%.

Savara Inc. (SVRA) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, particularly autoimmune pulmonary alveolar proteinosis (aPAP). Their lead drug candidate, Molbreevi (molgramostim inhalation solution), is currently in Phase 3 development for aPAP and is delivered via a proprietary eFlow Nebulizer System.

Groups SVRA belongs to

• Clinical Stage Biopharma
• Rare Diseases
• Biotechnology
• Pharmaceuticals
• Healthcare
• Biopharmaceutical
• Autoimmune Diseases
• Biologics
• Life Sciences
• Clinical Stage

SVRA financial model: income statement, cash flow and balance sheet